Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
Primary Industries
- Drugs
- Cancer
- Therapeutic
- Pharmaceuticals
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 28618
Licensor and its Affiliates developed expertise and acquired proprietary rights related to selective estrogen receptor modulator compounds ('SERMS') which are selective for Estrogen Receptor ('ER')(alpha) ('ER(alpha)') in U2OS cells (the 'ER(alpha)SELECTIVITY'
IPSCIO Record ID: 289168
Licensor grants Licensee under the Licensor Patents, Licensor Know-How and Licensors interest in the Research Technology and the Research Technology Patent Rights
— a non-exclusive, worldwide, right and license, without the right to sub license, solely to conduct its Research activities pursuant to this Agreement during the Research Term; and
— if Licensee exercises its License Option, commencing at the expiration of the Research Term and for a period of 3 years thereafter, a non-exclusive, worldwide, right and license, with the right to sub license solely to optimize, and, in connection with Licensees activities under this Agreement, make and use, but not sell, offer for sale or import, solely in connection with such optimization, Released Compounds for use in the Field.
Licensor grants Licensee an exclusive option during, the 4 month period following each decision by Licensor not to advance any particular Candidate Compound as either a Clinical Development Compound or Back-Up Compound, to obtain an exclusive, including with regard to Licensor, world-wide, right and license, with the right to sublicense, under the Licensor Patents and Licensor Know-How solely to conduct development on, and to make, have made and use for such purpose, any such Released Compounds for use in the Field, and to make, have made, import, use, sell and offer for sale pharmaceutical products containing or comprising any such Released Compounds in any formulation, each, a Released Product, for use in the Field.
Licensed Product means any product, including any formulation thereof, containing or comprising a Clinical Development Compound for use within the Field.
Licensor will initially provide Licensee with approximately [0.5 micromoles] each of approximately four hundred thousand (400,000) compounds, each an Licensor Compound in a 384 well format.
Caspases are a family of protease enzymes playing essential roles in programmed cell death.
IPSCIO Record ID: 203285
Licensor grants a non-transferable, non-exclusive license, with the right to sublicense, under the Licensor Other Patent Rights solely to the extent reasonably necessary to make, use (including in activities directed at the research and Development of Licensed Compounds), have made, sell, offer to sell, export and import and otherwise exploit or Commercialize Licensed Compounds and Licensed Products in the Field in the Territory.
6,670,386 – Bicyclic modulators of androgen receptor function
The licensed compounds and patents relate to controlling various diseases and cancers.
IPSCIO Record ID: 203240
For commercialization, Licensor grants to the Licensee of England, the exclusive, right and license in the Territory, with the right to grant sublicenses, under all of Licensors rights, title and interest in and to the Licensors Technology, to make, have made, use, sell, offer for sale and import the Progressed Compounds which are the subject of each of such Product Options as and into Product Candidates and as and into Licensed Products in the Field during the Term of this Agreement.
For Trademarks for licensed Products, Licensor shall assign its rights and title to such trademark(s) to Licensee, upon request.
Licensor grants the exclusive right, exercisable at Licensees sole discretion, to elect to obtain exclusive worldwide rights to continue to develop and commercialize at least four (4) and no more than six (6) Option Compounds (and their associated Back-up Compounds), as Product Candidates and into Licensed Products.
The patents include Sulfonamides, Piperazines and derivatives for inflammation and immunes.
Traficet-EN is intended to control the inflammatory response underlying inflammatory bowel disease, or IBD, by targeting the chemokine receptor known as CCR9. In adults, CCR9 is found primarily on a population of T cells, a subset of the body’s inflammatory cells, that migrate selectively to the digestive tract.
CCX354 targets the chemokine receptor known as CCR1. Synovial fluid from the joints of RA patients contains high levels of activated CCR1 chemokine ligands. Blocking CCR1 is intended to reduce inflammation and prevent subsequent joint destruction by suppressing the infiltration of inflammatory cells into the arthritic joint.
Traficet-EN (CCX282 or GSK’786) — Our most advanced drug candidate, currently in three pivotal Phase III clinical trials being conducted by our partner for the treatment of patients with moderate-to-severe Crohn’s disease.
Field shall mean any use or purpose, including without limitation the treatment, palliation, and/or prevention of any human or animal disease, disorder or condition; provided, however, that the Field shall specifically exclude the commercialization of protein therapeutics directed against Collaboration Targets.
